{"id":"pingyangmycin-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Pulmonary toxicity/fibrosis"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pingyangmycin is a glycopeptide antibiotic derived from Streptomyces pingyangensis that functions as a DNA-damaging agent. It binds to DNA and generates reactive oxygen species, causing double-strand breaks and inhibiting DNA synthesis. This mechanism makes it effective as a chemotherapeutic agent, particularly for squamous cell carcinomas and lymphomas.","oneSentence":"Pingyangmycin is a bleomycin-type antibiotic that intercalates into DNA and causes strand breaks, leading to cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:18.849Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Squamous cell carcinoma"},{"name":"Lymphoma"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT07197541","phase":"PHASE4","title":"A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10-01","conditions":"Plantar Wart","enrollment":200},{"nctId":"NCT05362253","phase":"NA","title":"Micro-Conjunctival Autografting Combined With Amniotic Membrane Transplantation Treating Recurrent Pterygium Trial","status":"COMPLETED","sponsor":"Yifeng Yu","startDate":"2021-03-01","conditions":"Recurrent Pterygium, Micro-Conjunctival Autografting Combined With Amniotic Membrane Transplantation","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pingyangmycin Injection","genericName":"Pingyangmycin Injection","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pingyangmycin is a bleomycin-type antibiotic that intercalates into DNA and causes strand breaks, leading to cell death. Used for Squamous cell carcinoma, Lymphoma, Head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}